Pathogenic and protective functions of TNF in neuroinflammation are defined by its expression in T lymphocytes and myeloid cells

Journal of Immunology

Volumn 187, Issue 11, 2011, Pages 5660-5670

  Kruglov, Andrey A ^a,b,c   Lampropoulou, Vicky ^a   Fillatreau, Simon ^a   Nedospasov, Sergei A ^a,b,c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b ENGELHARDT INSTITUTE OF MOLECULAR BIOLOGY   (Russian Federation)

^c MOSCOW STATE UNIVERSITY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 12P40; INTERLEUKIN 6; TUMOR NECROSIS FACTOR;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CONTROLLED STUDY; CYTOKINE PRODUCTION; INFLAMMATION; INFLAMMATORY CELL; INFLAMMATORY INFILTRATE; LYMPHOID ORGAN; MOUSE; NEUROPROTECTION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; T LYMPHOCYTE; TH1 CELL; TH17 CELL;

ANIMALS; CELL SEPARATION; CHEMOKINES; CHEMOTAXIS, LEUKOCYTE; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; LYMPHOCYTE ACTIVATION; MICE; MICE, KNOCKOUT; MYELOID CELLS; REAL-TIME POLYMERASE CHAIN REACTION; SPINAL CORD; SPLEEN; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 82755164848     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1100663     Document Type: Article

References (47)

1. Kruglov, A. A., A. Kuchmiy, S. I. Grivennikov, A. V. Tumanov, D. V. Kuprash, and S. A. Nedospasov. 2008. Physiological functions of tumor necrosis factor and the consequences of its pathologic overexpression or blockade: mouse models. Cytokine Growth Factor Rev. 19: 231-244.
2. Apostolaki, M., M. Armaka, P. Victoratos, and G. Kollias. 2010. Cellular mechanisms of TNF function in models of inflammation and autoimmunity. Curr. Dir. Autoimmun. 11: 1-26.
3. Feldmann, M., and R. N. Maini. 2001. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu. Rev. Immunol. 19: 163-196. (Pubitemid 32368033)
4. Ruddle, N. H., C. M. Bergman, K. M. McGrath, E. G. Lingenheld, M. L. Grunnet, S. J. Padula, and R. B. Clark. 1990. An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis. J. Exp. Med. 172: 1193-1200. (Pubitemid 20343220)
5. Baker, D., D. Butler, B. J. Scallon, J. K. O'Neill, J. L. Turk, and M. Feldmann. 1994. Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF receptor-immunoglobulin fusion proteins. Eur. J. Immunol. 24: 2040-2048.
6. Murphy, C. A., R. M. Hoek, M. T. Wiekowski, S. A. Lira, and J. D. Sedgwick. 2002. Interactions between hemopoietically derived TNF and central nervous system-resident glial chemokines underlie initiation of autoimmune inflammation in the brain. J. Immunol. 169: 7054-7062. (Pubitemid 36899293)
7. Körner, H., D. S. Riminton, D. H. Strickland, F. A. Lemckert, J. D. Pollard, and J. D. Sedgwick. 1997. Critical points of tumor necrosis factor action in central nervous system autoimmune inflammation defined by gene targeting. J. Exp. Med. 186: 1585-1590. (Pubitemid 27479818)
8. Liu, J., M. W. Marino, G. Wong, D. Grail, A. Dunn, J. Bettadapura, A. J. Slavin, L. Old, and C. C. Bernard. 1998. TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination. Nat. Med. 4: 78-83. (Pubitemid 28133083)
9. Arnett, H. A., J. Mason, M. Marino, K. Suzuki, G. K. Matsushima, and J. P. Ting. 2001. TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination. Nat. Neurosci. 4: 1116-1122. (Pubitemid 34116557)
10. Kassiotis, G., and G. Kollias. 2001. Uncoupling the proinflammatory from the immunosuppressive properties of tumor necrosis factor (TNF) at the p55 TNF receptor level: implications for pathogenesis and therapy of autoimmune demyelination. J. Exp. Med. 193: 427-434. (Pubitemid 32524474)
11. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. 1999. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 53: 457-465.
12. Lozeron, P., C. Denier, C. Lacroix, and D. Adams. 2009. Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy. Arch. Neurol. 66: 490-497.
13. Aggarwal, B. B. 2003. Signalling pathways of the TNF superfamily: a double-edged sword. Nat. Rev. Immunol. 3: 745-756. (Pubitemid 41070815)
14. Grivennikov, S. I., A. V. Tumanov, D. J. Liepinsh, A. A. Kruglov, B. I. Marakusha, A. N. Shakhov, T. Murakami, L. N. Drutskaya, I. Förster, B. E. Clausen, et al. 2005. Distinct and nonredundant in vivo functions of TNF produced by t cells and macrophages/neutrophils: protective and deleterious effects. Immunity 22: 93-104. (Pubitemid 40143454)
15. Selmaj, K., C. S. Raine, B. Cannella, and C. F. Brosnan. 1991. Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J. Clin. Invest. 87: 949-954.
16. Benvenuto, R., M. Paroli, C. Buttinelli, A. Franco, V. Barnaba, C. Fieschi, and F. Balsano. 1991. Tumour necrosis factor-alpha synthesis by cerebrospinal-fluid-derived T cell clones from patients with multiple sclerosis. Clin. Exp. Immunol. 84: 97-102.
17. Tumanov, A. V., S. I. Grivennikov, A. A. Kruglov, Y. V. Shebzukhov, E. P. Koroleva, Y. Piao, C. Y. Cui, D. V. Kuprash, and S. A. Nedospasov. 2010. Cellular source and molecular form of TNF specify its distinct functions in organization of secondary lymphoid organs. Blood 116: 3456-3464.
18. Lampropoulou, V., K. Hoehlig, T. Roch, P. Neves, E. Calderón Gómez, C. H. Sweenie, Y. Hao, A. A. Freitas, U. Steinhoff, S. M. Anderton, and S. Fillatreau. 2008. TLR-activated B cells suppress T cell-mediated autoimmunity. J. Immunol. 180: 4763-4773.
19. Kuprash, D. V., A. V. Tumanov, D. J. Liepinsh, E. P. Koroleva, M. S. Drutskaya, A. A. Kruglov, A. N. Shakhov, E. Southon, W. J. Murphy, L. Tessarollo, et al. 2005. Novel tumor necrosis factor-knockout mice that lack Peyer's patches. Eur. J. Immunol. 35: 1592-1600. (Pubitemid 40691439)
20. Sospedra, M., and R. Martin. 2005. Immunology of multiple sclerosis. Annu. Rev. Immunol. 23: 683-747. (Pubitemid 40563183)
21. Godiska, R., D. Chantry, G. N. Dietsch, and P. W. Gray. 1995. Chemokine expression in murine experimental allergic encephalomyelitis. J. Neuroimmunol. 58: 167-176.
22. Ma, X., J. Sun, E. Papasavvas, H. Riemann, S. Robertson, J.Marshall, R. T. Bailer, A. Moore, R. P. Donnelly, G. Trinchieri, and L. J. Montaner. 2000. Inhibition of IL-12 production in human monocyte-derived macrophages by TNF. J. Immunol. 164: 1722-1729. (Pubitemid 30108721)
23. Notley, C. A., J. J. Inglis, S. Alzabin, F. E. McCann, K. E. McNamee, and R. O. Williams. 2008. Blockade of tumor necrosis factor in collagen-induced arthritis reveals a novel immunoregulatory pathway for Th1 and Th17 cells. J. Exp. Med. 205: 2491-2497.
24. Zakharova, M., and H. K. Ziegler. 2005. Paradoxical anti-inflammatory actions of TNF-alpha: inhibition of IL-12 and IL-23 via TNF receptor 1 in macrophages and dendritic cells. J. Immunol. 175: 5024-5033. (Pubitemid 41456385)
25. Kassiotis, G., M. Pasparakis, G. Kollias, and L. Probert. 1999. TNF accelerates the onset but does not alter the incidence and severity of myelin basic protein-induced experimental autoimmune encephalomyelitis. Eur. J. Immunol. 29: 774-780. (Pubitemid 29119056)
26. Kroenke, M. A., T. J. Carlson, A. V. Andjelkovic, and B. M. Segal. 2008. IL-12-and IL-23-modulated T cells induce distinct types of EAE based on histology, CNS chemokine profile, and response to cytokine inhibition. J. Exp. Med. 205: 1535-1541. (Pubitemid 351962016)
27. Huitinga, I., N. van Rooijen, C. J. de Groot, B. M. Uitdehaag, and C. D. Dijkstra. 1990. Suppression of experimental allergic encephalomyelitis in Lewis rats after elimination of macrophages. J. Exp. Med. 172: 1025-1033. (Pubitemid 20343201)
28. Hofman, F. M., D. R. Hinton, K. Johnson, and J. E. Merrill. 1989. Tumor necrosis factor identified in multiple sclerosis brain. J. Exp. Med. 170: 607-612. (Pubitemid 19204288)
29. Elhofy, A., K. J. Kennedy, B. T. Fife, and W. J. Karpus. 2002. Regulation of experimental autoimmune encephalomyelitis by chemokines and chemokine receptors. Immunol. Res. 25: 167-175. (Pubitemid 34264102)
30. Alt, C., M. Laschinger, and B. Engelhardt. 2002. Functional expression of the lymphoid chemokines CCL19 (ELC) and CCL 21 (SLC) at the blood-brain barrier suggests their involvement in G-protein-dependent lymphocyte recruitment into the central nervous system during experimental autoimmune encephalomyelitis. Eur. J. Immunol. 32: 2133-2144. (Pubitemid 34965876)
31. Fife, B. T., K. J. Kennedy, M. C. Paniagua, N. W. Lukacs, S. L. Kunkel, A. D. Luster, and W. J. Karpus. 2001. CXCL10 (IFN-gamma-inducible protein-10) control of encephalitogenic CD4+ T cell accumulation in the central nervous system during experimental autoimmune encephalomyelitis. J. Immunol. 166: 7617-7624. (Pubitemid 32525644)
32. Izikson, L., R. S. Klein, I. F. Charo, H. L. Weiner, and A. D. Luster. 2000. Resistance to experimental autoimmune encephalomyelitis in mice lacking the CC chemokine receptor (CCR)2. J. Exp. Med. 192: 1075-1080.
33. Rottman, J. B., A. J. Slavin, R. Silva, H. L. Weiner, C. G. Gerard, and W. W. Hancock. 2000. Leukocyte recruitment during onset of experimental allergic encephalomyelitis is CCR1 dependent. Eur. J. Immunol. 30: 2372-2377.
34. Thompson, W. L., and L. J. Van Eldik. 2009. Inflammatory cytokines stimulate the chemokines CCL2/MCP-1 and CCL7/MCP-3 through NFkB and MAPK dependent pathways in rat astrocytes. [Published erratum appears in 2009 Brain Res. 1295: 230.] Brain Res. 1287: 47-57.
35. McManus, C., J. W. Berman, F. M. Brett, H. Staunton, M. Farrell, and C. F. Brosnan. 1998. MCP-1, MCP-2 and MCP-3 expression in multiple sclerosis lesions: an immunohistochemical and in situ hybridization study. J. Neuroimmunol. 86: 20-29. (Pubitemid 28293946)
36. Ransohoff, R. M., T. A. Hamilton, M. Tani, M. H. Stoler, H. E. Shick, J. A. Major, M. L. Estes, D. M. Thomas, and V. K. Tuohy. 1993. Astrocyte expression of mRNA encoding cytokines IP-10 and JE/MCP-1 in experimental autoimmune encephalomyelitis. FASEB J. 7: 592-600. (Pubitemid 23120908)
37. Columba-Cabezas, S., B. Serafini, E. Ambrosini, and F. Aloisi. 2003. Lymphoid chemokines CCL19 and CCL21 are expressed in the central nervous system during experimental autoimmune encephalomyelitis: implications for the maintenance of chronic neuroinflammation. Brain Pathol. 13: 38-51. (Pubitemid 36133791)
38. Haak, S., A. L. Croxford, K. Kreymborg, F. L. Heppner, S. Pouly, B. Becher, and A. Waisman. 2009. IL-17A and IL-17F do not contribute vitally to autoimmune neuro-inflammation in mice. J. Clin. Invest. 119: 61-69.
39. Ferber, I. A., S. Brocke, C. Taylor-Edwards,W. Ridgway, C. Dinisco, L. Steinman, D. Dalton, and C. G. Fathman. 1996. Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE). J. Immunol. 156: 5-7.
40. Codarri, L., G. Gyülvészi, V. Tosevski, L. Hesske, A. Fontana, L. Magnenat, T. Suter, and B. Becher. 2011. RORγt drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nat. Immunol. 12: 560-567.
41. Langrish, C. L., Y. Chen, W. M. Blumenschein, J. Mattson, B. Basham, J. D. Sedgwick, T. McClanahan, R. A. Kastelein, and D. J. Cua. 2005. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 201: 233-240. (Pubitemid 40189432)
42. Cherwinski, H. M., J. H. Schumacher, K. D. Brown, and T. R. Mosmann. 1987. Two types of mouse helper T cell clone. III. Further differences in lymphokine synthesis between Th1 and Th2 clones revealed by RNA hybridization, functionally monospecific bioassays, and monoclonal antibodies. J. Exp. Med. 166: 1229-1244. (Pubitemid 18051419)
43. Shen, F., and S. L. Gaffen. 2008. Structure-function relationships in the IL-17 receptor: implications for signal transduction and therapy. Cytokine 41: 92-104.
44. Kang, Z., C. Z. Altuntas, M. F. Gulen, C. Liu, N. Giltiay, H. Qin, L. Liu, W. Qian, R. M. Ransohoff, C. Bergmann, et al. 2010. Astrocyte-restricted ablation of interleukin-17-induced Act1-mediated signaling ameliorates autoimmune encephalomyelitis. Immunity 32: 414-425.
45. Longbrake, E. E., and M. K. Racke. 2009. Why did IL-12/IL-23 antibody therapy fail in multiple sclerosis? Expert Rev. Neurother. 9: 319-321.
46. Kassiotis, G., K. Kranidioti, and G. Kollias. 2001. Defective CD4T cell priming and resistance to experimental autoimmune encephalomyelitis in TNF-deficient mice due to innate immune hypo-responsiveness. J. Neuroimmunol. 119: 239-247. (Pubitemid 32918332)
47. Fabis, M. J., G. S. Scott, R. B. Kean, H. Koprowski, and D. C. Hooper. 2007. Loss of blood-brain barrier integrity in the spinal cord is common to experimental allergic encephalomyelitis in knockout mouse models. Proc. Natl. Acad. Sci. USA 104: 5656-5661. (Pubitemid 47175736)